The global extracorporeal membrane oxygenation market was valued at US$ 546.73 million in 2021 and is projected to reach US$ 677.64 million by 2028. The market is estimated to grow at a CAGR of 3.1% during 2022–2028.

Extracorporeal membrane oxygenation (extracorporeal membrane oxygenation) is a treatment used for blood circulation through an artificial lung. The system helps provide heart-lung bypass route outside the body. This also provides support to patients who need a lung transplant. The extracorporeal membrane oxygenation market growth is attributed to the rising prevalence of cardiovascular diseases and respiratory failures and the growing adoption of extracorporeal membrane oxygenation in lung transplantation procedures. However, complications associated with extracorporeal membrane oxygenation hinder the growth of the market.

Market Insights

Growing Adoption of extracorporeal membrane oxygenation in Lung Transplantation Procedures Drive extracorporeal membrane oxygenation Market Growth

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Extracorporeal Membrane Oxygenation Market: Strategic Insights

Extracorporeal Membrane Oxygenation Market

• 
  CAGR (2021 - 2028)

  3.1%
• Market Size 2021
  US$ 546.73 Million
• Market Size 2028
  US$ 677.64 Million

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Terumo Group
• Medtronic Plc
• MicroPort Scientific Corporation
• LivaNova Plc
• Nipro Medical Corporation
• Eurosets S.R.L.
• Getinge AB
• Braile Biomedica
• Fresenius Medical Care AG & Co KGaA

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Modality

• Venoarterial extracorporeal membrane oxygenation
• Venovenous extracorporeal membrane oxygenation
• Arteriovenous extracorporeal membrane oxygenation

Application

• Respiratory and Cardiology

Age Group

• Adults
• Pediatrics
• Neonates

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life. extracorporeal membrane oxygenation is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods. It acts as a bridge for patient undergoing lung transplantation. Therefore, the adoption of extracorporeal membrane oxygenation during lung transplantation is growing rapidly to manage patients with life-threatening lung disease. According to the Scientific Registry of Transplant Recipients (SRTR), ~4,600 lung transplants are performed across the world every year, of which 55% were performed in North America. According to the same source, ~2,759 patients underwent lung transplantation, and ~3,243 patients were added to the lung transplant waiting list in the US. Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant. Thus, extracorporeal membrane oxygenation is used penultimately in treating PGD post lung transplantation. According to National Library Medicine (NLM), in 2022, the overall incidence of PGD is 30%, in which the risk factors include preoperative donor lung ischemia, organ acquisition, preservation techniques, and intraoperative organ implantation and reperfusion. Thus, the demand for extracorporeal membrane oxygenation equipment is growing for treating patients suffering from PGD.

Modality-Based Insights

The global extracorporeal membrane oxygenation market, based on modality, is segmented into venoarterial extracorporeal membrane oxygenation, venovenous extracorporeal membrane oxygenation, and arteriovenous extracorporeal membrane oxygenation. The venoarterial extracorporeal membrane oxygenation segment held the largest share of the market in 2021. Moreover, the same segment is anticipated to register a highest CAGR of 3.8% in the market during the forecast period. Venoarterial (VA) extracorporeal membrane oxygenation supports the patient's heart and lungs by pushing the blood through the circuit without getting through the patient's heart. This type of extracorporeal membrane oxygenation takes blood out of a large vein and back it into a large artery, allowing oxygen-rich blood to circulate through the body even if the heart is too weak to pump. Veno-arterial extracorporeal membrane oxygenation (VA-extracorporeal membrane oxygenation) has been widely applied over the last decade. It is an effective and valuable therapeutic option in refractory cardiogenic shock of various etiologies. It showed promising results in the specific setting of in-hospital cardiac arrest, and survival rates with good neurological outcomes are reported between 20% and 40%.

Age Group-Based Insights

Based on age group, the global extracorporeal membrane oxygenation market is segmented into adults, pediatrics and neonates. The adults segment held the largest share of the market in 2021 and is expected to register a CAGR of 3.7% during 2022–2028. The extracorporeal membrane oxygenation help the adult patients suffering from cardiac or respiratory failure. Moreover, the recent technological advancements in extracorporeal membrane oxygenation circuits have led to reduction in the rate of technical issues and complication.

Extracorporeal Membrane Oxygenation – Market Segmentation

The extracorporeal membrane oxygenation market is segmented on the basis of modality, application, age group, and geography. Based on modality, the market is segmented into venoarterial extracorporeal membrane oxygenation, venovenous extracorporeal membrane oxygenation, arteriovenous extracorporeal membrane oxygenation. Based on application, the extracorporeal membrane oxygenation market is bifurcated into respiratory and cardiology. In terms of end user, the extracorporeal membrane oxygenation market is segmented into adults, pediatrics, and neonates. By geography, the extracorporeal membrane oxygenation market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). 

Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios to dominate the extracorporeal membrane oxygenation market share. Moreover, the market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. The market is anticipated to flourish in the coming years owing to the development of new innovative products by market players.

Extracorporeal Membrane Oxygenation Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Company Profiles

• Terumo Group
• Medtronic Plc
• MicroPort Scientific Corporation
• LivaNova Plc
• Nipro Medical Corporation
• Eurosets S.R.L.
• Getinge AB
• Braile Biomedica
• Fresenius Medical Care AG & Co KGaA
• ABIOMED Inc